Ophidian Pharmaceuticals, Inc.
Records under this name other than patents Ophidian Pharmaceuticals, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Ophidian Pharmaceuticals, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,967,088 | Soluble recombinant botulinum toxin proteins Formerly held Lapsed on the fee record Ended Nov 22, 2013 · USPTO record | Lapsed on the fee record | Ended Nov 22, 2013 | USPTO record |
| US 6,290,960 | Vaccine and antitoxin for the treatment of C. difficile disease Formerly held Lapsed on the fee record Ended Sep 18, 2013 · USPTO record | Lapsed on the fee record | Ended Sep 18, 2013 | USPTO record |
| US 6,214,343 | Prevention and treatment of necrotizing enterocolitis Formerly held Lapsed on the fee record Ended Apr 10, 2013 · USPTO record | Lapsed on the fee record | Ended Apr 10, 2013 | USPTO record |
| US 7,494,652 | Treatment of sepsis Formerly held Lapsed on the fee record Ended Feb 24, 2013 · USPTO record | Lapsed on the fee record | Ended Feb 24, 2013 | USPTO record |
| US 6,080,400 | Compositions for the prevention and treatment of verotoxin-induced disease Formerly held Lapsed on the fee record Ended Jun 27, 2012 · USPTO record | Lapsed on the fee record | Ended Jun 27, 2012 | USPTO record |
| US 6,663,864 | Antibodies to cytokines in the prevention and treatment of inflammatory bowel disease Formerly held Lapsed on the fee record Ended Dec 16, 2011 · USPTO record | Lapsed on the fee record | Ended Dec 16, 2011 | USPTO record |
| US 6,395,273 | Prevention and treatment of inflammatory bowel disease Formerly held Lapsed on the fee record Ended May 28, 2010 · USPTO record | Lapsed on the fee record | Ended May 28, 2010 | USPTO record |
| US 6,346,247 | Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies Formerly held Lapsed on the fee record Ended Feb 12, 2010 · USPTO record | Lapsed on the fee record | Ended Feb 12, 2010 | USPTO record |
| US 6,613,329 | Vaccine and antitoxin for treatment and prevention of C. difficile disease Formerly held Term ended Ended no later than Oct 31, 2009 · USPTO record | Term ended | Ended no later than Oct 31, 2009 | USPTO record |
| US 6,046,165 | Compositions and methods for identifying and testing TGF-.beta. pathway agonists and antagonists Formerly held Lapsed on the fee record Ended Apr 4, 2008 · USPTO record | Lapsed on the fee record | Ended Apr 4, 2008 | USPTO record |